Merck & Co. Touts $6.7B Terns Deal, Highlights TERN-701 “Best-in-Class” CML Potential

Core Insights - Merck's acquisition of Terns Pharmaceuticals is primarily focused on TERN-701, a next-generation allosteric TKI for chronic myeloid leukemia (CML), which is expected to address unmet needs in the treatment landscape [2][4][6] Company Strategy - Merck's strategy emphasizes a science-led approach to business development, aiming to diversify its pipeline, particularly in oncology, with over 20 anticipated new growth drivers projected to represent a combined commercial opportunity exceeding $70 billion by the mid-2030s [3][4] Acquisition Details - The acquisition of Terns is valued at approximately $6.7 billion, with Merck agreeing to pay $53 per share, and the deal is expected to close in the second quarter of 2026, pending regulatory approvals [7][19] - Merck plans to account for the acquisition as an asset acquisition, anticipating a $5.8 billion R&D charge in 2026 and a negative EPS impact of approximately $0.17 in the first year [5][19] Product Potential - TERN-701 is positioned as potentially "best-in-class," with early clinical data showing promising efficacy and tolerability compared to existing TKIs, including higher rates of major molecular response (MMR) and deep molecular response (DMR) [6][9][10] - The drug targets an allosteric site on the ABL protein, aiming to overcome resistance mutations and minimize off-target effects, which could support higher dosing and more complete inhibition [8][10] Market Opportunity - CML is a chronic disease with an increasing prevalence, with an estimated 18,000 new patients diagnosed annually in the U.S., key European markets, and Japan [14] - Merck anticipates that TERN-701 could become a significant growth driver starting in the early 2030s, with a multibillion-dollar revenue potential [15] Competitive Landscape - Merck does not foresee significant barriers to market access for TERN-701, even amid generic competition for earlier-generation TKIs, and expects that differentiated clinical data will support its uptake [16]